{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-074469","form_type":"8-K","ticker":null,"cik":"0000316253","company_name":"ENZO BIOCHEM INC","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.242176+00:00","generated_at":"2026-06-10T23:04:01.617083+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CEO Hamid Erfanian resigns; COO Kara Cannon named Interim CEO","bullets":["CEO Hamid Erfanian resigned effective Sep 5, 2023; final employment date Nov 18, 2023.","Severance: $624k base (12 months), $187.2k bonus, $1.5M restricted stock grant, accelerated RSUs & options.","COO Kara Cannon appointed Interim CEO; base salary increased from $308k to $350k.","Company shifts focus to life sciences division after divestiture of Enzo Clinical Lab."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-074469","json":"https://secwatch.observer/filing/0001213900-23-074469.json","markdown":"https://secwatch.observer/filing/0001213900-23-074469.md","text":"https://secwatch.observer/filing/0001213900-23-074469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/316253/000121390023074469/0001213900-23-074469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/316253/000121390023074469/ea184646-8k_enzobio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:04:01.617083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42966b458a","claim":"Hamid Erfanian resigned as Chief Executive Officer at ENZO BIOCHEM INC.","evidence_excerpt":"On September 5, 2023, Enzo Biochem, Inc. (the “Company”) entered into a Separation Agreement and General Release (the “Separation Agreement”) with Hamid Erfanian, the Company’s Chief Executive Officer, which provides for Mr. Erfanian’s separation of employment, resignations from his positions as Chief Executive Officer and as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390023074469/0001213900-23-074469-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"80daf3eb43","claim":"Kara Cannon was appointed as Interim Chief Executive Officer at ENZO BIOCHEM INC.","evidence_excerpt":"the Company’s board of directors appointed Kara Cannon, the Company’s Chief Operating Officer, to serve as Interim Chief Executive Officer of the Company, effective immediately upon Mr. Erfanian’s resignation as Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390023074469/0001213900-23-074469-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"8f63dfb6c9","claim":"Hamid Erfanian resigned as Director at ENZO BIOCHEM INC.","evidence_excerpt":"Pursuant to the Separation Agreement, Mr. Erfanian’s resignations as Chief Executive Officer and as a director are effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/316253/000121390023074469/0001213900-23-074469-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}